PARP1 and ovarian carcinoma: The full significance of somatic BRCA mutations as a biomarker for the prediction of therapeutic response to PARP inhibition is not entirely clear but ovarian cancer patients with a somatic BRCA mutation are equally likely to benefit from treatment with PARP inhibitors as those with a germline mutation of BRCA. Some authors suggest to perform somatic BRCA testing in routine clinical diagnostics of all advanced tumors, which are potentially amenable to PARP inhibitors [3, 6–11].